Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
spirulina-based malaria vaccine
- Development stage
- Preclinical
- Lead developer
- Lumen Bioscience
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intranasal, Oral
01
Overview
This spirulina-based malaria vaccine is an investigational intranasal and oral vaccine developed by Lumen Bioscience for the prevention of malaria. The vaccine utilizes genetically engineered spirulina (Arthrospira platensis), a photosynthetic cyanobacterium, to express virus-like particles (VLPs) that display the NANP repeat region of the Plasmodium falciparum circumsporozoite protein (PfCSP). Administered as an intranasal prime followed by oral booster doses, the vaccine is designed to induce both systemic and mucosal immune responses, targeting the pre-erythrocytic stage of the parasite to prevent liver infection. The platform offers a low-cost, scalable, and shelf-stable alternative to traditional vaccines, potentially eliminating the need for cold-chain logistics and trained medical personnel in endemic regions.
- Other names
- intranasal malaria vaccine
02
Targets
CSP (Circumsporozoite protein)
Beyond the preview
Go deeper on spirulina-based malaria vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on spirulina-based malaria vaccine.